. Author manuscript; available in PMC: 2014 Jul 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2013 Apr 10;19(7):1033–1039. doi: 10.1016/j.bbmt.2013.04.005

Table 4.

Relationship between exposure to CY and its metabolites and clinical outcomes among cases conditioned with CY/^TBU.^a

Clinical Outcome	N^b	Pharmacokinetic Parameters
Clinical Outcome	N^b	AUC_CY	AUC_HCY	AUC_CEPM
Non-relapse mortality	10	HR=1.15 (p=0.64)	HR=1.67 (p=0.11)	HR=1.40(p=0.25)
Relapse	9	HR=1.05 (p=0. 84)	HR=1.2 (p=0.53)	HR=1.53 (p=0.10)
Overall mortality	20	HR=1.28 (p=0.26)	HR=1.74 (p=0.03)	HR=1.67(p=0.02)

AUC modeled as continuous linear variable, with hazard ratios for AUC_CEPM and AUC_HCY representing increase in hazard ratio (HR) associated with increase in AUC of 100 μM•h. Hazard ratios for AUC_CY represent increase in hazard associated with increase in AUC of 1000 μM•h. Hazard ratios adjusted for age at time of HCT, type of donor, and relapse risk.

Number of events in cohort in 51 cases.

Abbreviations: CY, cyclophosphamide; ^TBU, targeted busulfan; HR, hazard ratio; AUC, area under the curve; HCY, 4-hydroxycyclophosphamide; CEPM, carboxyethylphosphoramide mustard.